Introduction of biosimilar biologics will not bring about the same price drops as introduction of generic small-molecule drugs, said Rena Conti, an economist at the University of Chicago, whose work focuses on drug pricing.
Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality. It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...
